There has never been a more exciting—and let’s be honest, chaotic—time in Retina than right now. It feels as though new drugs are rolling onto the market almost every quarter. After Eylea® rolled out in 2011, we didn’t see new therapies introduced to the clinic until Susvimo™ and Vabysmo® came out last year. This year, we have geographic atrophy drugs on the market giving us new treatment options that we’ve never had before.